Please Be Sure That You Have Your Audience Response Keypad With You This Morning. You Will Need It During This Session.

Slides:



Advertisements
Similar presentations
© 2010, American Heart Association. All rights reserved. Are Quality Improvements Associated with the GWTG-Coronary Artery Disease (GWTG-CAD) Program Sustained.
Advertisements

Community Pharmacy Workbook
Nurse Led Clinics Opportunity for nurses to make a difference Wilma Scholte op Reimer, RN, PhD Amsterdam School of Health Professions Academic Medical.
Ideal Practice Workflow Revenue Maximization and Cost Efficiency Contact us : 2222 Morris Ave. 2nd Floor, Union, NJ Ph: (908)
LAKESIDE WELLNESS PROGRAM - PBHCI LEARNING COMMUNITY REGION #3 ORLANDO, FLORIDA, RUTH CRUZ- DIAZ, BSN EXT
Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.
How to improve the patient ADHERENCE to clinical trials ?
Hypertension Management: Thinking Outside the Protocol Seuli Bose Brill, MD ACC Ambulatory Conference January 7, 2009 Review of the ACCOMPLISH trial and.
JOB FUNCTION EVALUATION Lowering Your Accident Costs.
Canadian Diabetes Association Clinical Practice Guidelines Dyslipidemia Chapter 24 G. B. John Mancini, Robert A. Hegele, Lawrence A. Leiter.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Michigan Medical Home.
The North West Unified Do Not Attempt Cardio- Pulmonary Resuscitation Policy Presented by; Date: Acknowledgement to Integrated ACP Team Knowsley, St Helens.
Treating to New Targets Study TNT Trial Presented at The American College of Cardiology Scientific Sessions 2005 Presented by Dr. John C. LaRosa.
Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.
Consent for Research Study RESCUE: Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Diagnostic Examinations ACRIN
HEAL-IT Bauer Sumpio Yale University Suephy C. Chen, William S. Weintraub Emory University Sponsor: Otsuka America.
Commissioning home care for people experiencing dementia LUCIANNE SAWYER CBE UKHCA AND COMMUNITY CARE RESEARCH & CONSULTANCY.
Research Day Sustainable TeleHealthcare delivery model for diverse socio-economic communities in New York City.
Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.
ONTARGET Risk factors and outcomes associated with nonadherence Background ONTARGET compared the efficacy of the ARB telmisartan, the ACE inhibitor ramipril,
February is Heart & Stroke Awareness Month. Did you know???? Heart Disease and Stroke is Preventable if you know your RISK FACTORS.
Scheduling. Operation Protocol Send an application form to patients Receive the returned application form from patients Check doctor’s schedule Check.
1 Assessing and Improving ARV Adherence HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Prescribing Errors in General Practice The PRACtICe Study (2012) GMC Investigating Prevalence and Causes.
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College.
NFP CARE TEAM PATIENT ADVOCATE New Roles, New Possibilities.
BARI 2D Trial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans The Bypass Angioplasty.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
Cardiac Rehabilitation 2011 Update for Primary Care Providers Douglass A Morrison, MD, PhD Cardiac Rehabilitation, Medical Director Yakima Regional and.
Study Session Experimental Design. 1. Which of the following is true regarding the difference between an observational study and and an experiment? a)
AA-2-1 Jerome D. Cohen, MD, FACC, FACP Professor of Internal Medicine / Cardiology Director, Preventive Cardiology Programs St. Louis University Health.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
Nottingham City PCT1 Quality improvement to ensure health gain (and Health Inequalities reductions) an example: commissioning cardiovascular risk management.
Community Pharmacy Cheshire & Wirral (CPCW) Helen Murphy Chief Executive Officer Community Pharmacy Cheshire and Wirral.
CONAN HASSIM May AIMS By the end of this session, I hope you are More confident about primary care investigations. Provide some knowledge helpful.
Quality and Outcomes Framework Assessor Training Collecting and Analysing Data Module S4.
Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.
Acute Myocardial Infarction February 8, 2006.
Medidata Rave Start-Up Information
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults Scott W. Rypkema, M.D.
Sheffield Integrated Care Service Integrated support for complex patients. Sarah Alton Head of Medicines Management Janet Smith Community Matron.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Documentation in Practice Dept. of Clinical Pharmacy.
Patient Participation meeting Monday 11 February 2013
REFLECT: Recovery Following Intensive Care Treatment
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
MAINTAINING THE INVESTIGATOR’S SITE FILE
Research Questions Does integration of behavioral health and primary care services, compared to simple co-location, improve patient-centered outcomes in.
Douglas S. Bell, MD, PhD Leader, UCLA CTSI Informatics Program
Module 4: Role Playing and Case Discussions
Safi U. Khan MD; John Pamula MD
Introduction to Clinical Pharmacy
Pravastatin in Elderly Individuals at Risk of Vascular Disease
Section 9: Continuum of care: Summary and timeline
2006 CRUSADE 2nd Quarter Results
MAINTAINING THE INVESTIGATOR’S STUDY FILE
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
The Cardiovascular Inflammation Reduction Trial (CIRT)
Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Elevated Admission Plasma Glucose Following ACS
DECLARE-TIMI 58.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Goals & Guidelines A summary of international guidelines for CHD
Principles of Participation
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

Please Be Sure That You Have Your Audience Response Keypad With You This Morning. You Will Need It During This Session

How Many Electronic CRF Trials Have You Done? A. Only One B. 2-3 C. More than 3

What Other EDC Systems Have You Used? A. Datatrak B. e-trials C. Medidata D. Datatrak and e-trials E. e-trials and Medidata F. All three G. None of the Above

Which is the Easiest / Preferred System? A. Datatrak B. e-trials C. InForm D. Medidata E. Other System F. No Preference

Which is the Most Difficult System To use? A. Datatrak B. e-trials C. InForm D. Medidata E. Other System

Do You Prefer an Electronic CRF of Paper CRF? A. Electronic CRF B. Paper CRF

Clinical trials principles dictate that complete ascertainment of the primary endpoint gives the optimal chance of proving the objective. In the IMPROVE IT Trial, the primary endpoint is a composite of CV death, MI, UA, Stroke, and Revasc. If the subject withdraws from the trial and all visits, what happens in the ITT analysis? A.The subject is removed from the database and replaced with another subject who completed the entire trial. B.The subject is only analyzed in the safety analyses. C.The subject is analyzed up to the time of study withdrawal. D.The subjects data present at the time of study withdrawal is used for the remaining months of the trial in the analysis.

How should subjects be routinely managed to prevent study withdrawal? A.Schedule appointment and send reminder to the subject within 7 days. B.Schedule appointment at the end of the follow-up window to maximize the use of the study drug in the bottles (avoid waste). C.Schedule appointment and notify subject of date and time within 3 weeks of appointment. D.Maintain close contact with subject in between visits, schedule appointment when convenient for subject (be flexible), call to remind.

When is the best time to let the monitor know of a subject who is not available for follow-up? A.At the end of the trial B.After the subject has missed 1 visit C.After the subject has missed 2 visits (8-12 months) D.After the Research Team has performed all the suggested steps on the Lost to Follow Up Checklist form

If a subject expresses concern that she will not be available for the appointment within the time window and therefore wishes to finish their participation in the trial, what should the RC do? A.Communicate to the subject the need to stay on study drug. Make arrangements for the subject to see another MD in the practice B.Agree that the subject has participated for most of the study and it would be OK to finish. Continue phone contact for endpoints C.Skip that appointment and call the subject when (s)he is available.

What is the goal of Getting with the Guidelines – (GWTG)? A.To get MDs to prescribe ASA to CAD patients. B.To reduce bleeding rates to an acceptable level. C.To reduce death/disability of CHD/stroke by 25% by D.To illustrate to insurance companies that the optimal treatment is being given to the patient.

The GWTG is based on: A.The MDs personal experience. B.Evidence based medicine. C.The type of treatment options that are available: (PCI, CABG, nuclear equipment). D.Individual hospital survey.

Which one of the following is NOT a GWTG Performance Measure for Cardiovascular Disease? A. A.Perform PCI before hospital discharge B. B.Smoking Cessation Counseling C. C.ACE-I / ARB for LVSD on discharge D. D.Lipid lowering therapy on discharge

What characteristics are associated with statin use at hospital discharge? A. A.Renal insufficiency B. B.Age >60 yrs C. C.Absence of diabetes D. D.Measuring LDL in hospital

In following your IMPROVE-IT subjects do you discuss: A. A. Cessation of smoking B. B. Healthy food choices C. C. Increase physical activity D. D. All of the above

If a subject complains of persistent but mild headaches and wishes to come off study drug, what should the RC do? A. A.Agree and let patient know that it is possibly due to the study drug B. B.Acquire more information from patient, review con meds, and discuss w/PI the most likely reason for headaches C. C.Inform the patient there is nothing that can be done by that the patient should stay on study drug D. D.Give Tylenol to the patient

The PI is very busy with his/her private practice and does not have time to commit to IMPROVE-IT. What steps should the RC undertake? A. A.Perform trial tasks / responsibilities on his/her own. B. B.Seek support from the TIMI Hotline for questions. C. C.Participate in a meetings with PI to review specific areas where help / support is needed. D. D.Abandon efforts to recruit subjects

Lets Check the Standings

If You Are Attending the Monitor Training Session Take Your Audience Response Keypad With You. If You Are Not Attending the Monitor Training, Please Turn In Your Keypad IMMEDIATELY Following This Session at the Registration Tables.

Participant Scores 1100 Jose Saaibi 1000 Jose Nicolau Virginia Dawney Sebastian Nani María Cademartori